Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

120 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target.
Krystof V, Baumli S, Fürst R. Krystof V, et al. Among authors: furst r. Curr Pharm Des. 2012;18(20):2883-90. doi: 10.2174/138161212800672750. Curr Pharm Des. 2012. PMID: 22571657 Free PMC article. Review.
Twice switched at birth: cell cycle-independent roles of the "neuron-specific" cyclin-dependent kinase 5 (Cdk5) in non-neuronal cells.
Liebl J, Fürst R, Vollmar AM, Zahler S. Liebl J, et al. Among authors: furst r. Cell Signal. 2011 Nov;23(11):1698-707. doi: 10.1016/j.cellsig.2011.06.020. Epub 2011 Jun 30. Cell Signal. 2011. PMID: 21741478 Review.
Cyclin-dependent kinase 5 regulates endothelial cell migration and angiogenesis.
Liebl J, Weitensteiner SB, Vereb G, Takács L, Fürst R, Vollmar AM, Zahler S. Liebl J, et al. Among authors: furst r. J Biol Chem. 2010 Nov 12;285(46):35932-43. doi: 10.1074/jbc.M110.126177. Epub 2010 Sep 7. J Biol Chem. 2010. PMID: 20826806 Free PMC article.
Anti-angiogenic effects of purine inhibitors of cyclin dependent kinases.
Liebl J, Krystof V, Vereb G, Takács L, Strnad M, Pechan P, Havlicek L, Zatloukal M, Fürst R, Vollmar AM, Zahler S. Liebl J, et al. Among authors: furst r. Angiogenesis. 2011 Sep;14(3):281-91. doi: 10.1007/s10456-011-9212-6. Epub 2011 Apr 13. Angiogenesis. 2011. PMID: 21487803
The purine Cdk specific inhibitor (R)-roscovitine (seliciclib, CYC202) represents one of the most promising of these compounds. ...The (S)-isomer LGR561 and the respective (R)- and (S)-isomers LGR848 and LGR849 strongly inhibited proliferation and cell cycle progres …
The purine Cdk specific inhibitor (R)-roscovitine (seliciclib, CYC202) represents one of the most promising of these compounds. ...Th …
Roscovitine blocks leukocyte extravasation by inhibition of cyclin-dependent kinases 5 and 9.
Berberich N, Uhl B, Joore J, Schmerwitz UK, Mayer BA, Reichel CA, Krombach F, Zahler S, Vollmar AM, Fürst R. Berberich N, et al. Among authors: furst r. Br J Pharmacol. 2011 Jul;163(5):1086-98. doi: 10.1111/j.1476-5381.2011.01309.x. Br J Pharmacol. 2011. PMID: 21391976 Free PMC article.
Flavopiridol protects against inflammation by attenuating leukocyte-endothelial interaction via inhibition of cyclin-dependent kinase 9.
Schmerwitz UK, Sass G, Khandoga AG, Joore J, Mayer BA, Berberich N, Totzke F, Krombach F, Tiegs G, Zahler S, Vollmar AM, Fürst R. Schmerwitz UK, et al. Among authors: furst r. Arterioscler Thromb Vasc Biol. 2011 Feb;31(2):280-8. doi: 10.1161/ATVBAHA.110.213934. Epub 2010 Nov 18. Arterioscler Thromb Vasc Biol. 2011. PMID: 21088252
Anti-angiogenic potential of small molecular inhibitors of cyclin dependent kinases in vitro.
Zahler S, Liebl J, Fürst R, Vollmar AM. Zahler S, et al. Among authors: furst r. Angiogenesis. 2010 Sep;13(3):239-49. doi: 10.1007/s10456-010-9181-1. Epub 2010 Aug 13. Angiogenesis. 2010. PMID: 20706783
Narciclasine exerts anti-inflammatory actions by blocking leukocyte-endothelial cell interactions and down-regulation of the endothelial TNF receptor 1.
Stark A, Schwenk R, Wack G, Zuchtriegel G, Hatemler MG, Bräutigam J, Schmidtko A, Reichel CA, Bischoff I, Fürst R. Stark A, et al. Among authors: furst r. FASEB J. 2019 Aug;33(8):8771-8781. doi: 10.1096/fj.201802440R. Epub 2019 Apr 24. FASEB J. 2019. PMID: 31017817
., Schwenk, R., Wack, G., Zuchtriegel, G., Hatemler, M. G., Bräutigam, J., Schmidtko, A., Reichel, C. A., Bischoff, I., Fürst, R. ...
., Schwenk, R., Wack, G., Zuchtriegel, G., Hatemler, M. G., Bräutigam, J., Schmidtko, A., Reichel, C. A., Bischoff, I., Fürst, R
Structural modification of resveratrol leads to increased anti-tumor activity, but causes profound changes in the mode of action.
Scherzberg MC, Kiehl A, Zivkovic A, Stark H, Stein J, Fürst R, Steinhilber D, Ulrich-Rückert S. Scherzberg MC, et al. Among authors: furst r. Toxicol Appl Pharmacol. 2015 Aug 15;287(1):67-76. doi: 10.1016/j.taap.2015.05.020. Epub 2015 Jun 2. Toxicol Appl Pharmacol. 2015. PMID: 26044878
In vitro evaluation of a biomaterial-based anticancer drug delivery system as an alternative to conventional post-surgery bone cancer treatment.
Bischoff I, Tsaryk R, Chai F, Fürst R, Kirkpatrick CJ, Unger RE. Bischoff I, et al. Among authors: furst r. Mater Sci Eng C Mater Biol Appl. 2018 Dec 1;93:115-124. doi: 10.1016/j.msec.2018.07.057. Epub 2018 Jul 21. Mater Sci Eng C Mater Biol Appl. 2018. PMID: 30274043
120 results
Jump to page
Feedback